Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

64.63 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
3 Highly Rated Biotech Stocks for Your July Buy List ↗
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street. 
Via InvestorPlace
News headline image
3 Breakout Biotech Stocks on Track to Double by 2032 ↗
The tech sector has been at the forefront of the market rally in 2024. Consider these breakout biotech stocks as a great way to diversify. 
Via InvestorPlace
News headline image
UroGen Pharma Stock Earns 91 RS Rating ↗
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
News headline image
Don't overlook NASDAQ:HALO—a stock with solid growth prospects and a reasonable valuation. ↗
Investors seeking growth at a reasonable cost should explore HALOZYME THERAPEUTICS INC (NASDAQ:HALO). 
Via Chartmill
News headline image
Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval ↗
Sarepta Therapeutics had its Relative Strength (RS) Rating upgraded to 95 Monday, up from 68 a day earlier. 
Via Investor's Business Daily
News headline image
Decoding 12 Analyst Evaluations For Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
NASDAQ:HALO: a strong growth stock preparing for the next leg up?. ↗
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
NASDAQ:HALO, a growth stock which is not overvalued. ↗
NASDAQ:HALO stands out as a growth opportunity that won't break the bank. 
Via Chartmill
News headline image
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. ↗
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO. 
Via Chartmill
News headline image
Arcellx Stock Earns Relative Strength Rating Upgrade ↗
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
News headline image
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
News headline image
Don't overlook NASDAQ:HALO—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
The 3 Best Healthcare Stocks to Buy in June 2024 ↗
Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on. 
Via InvestorPlace
News headline image
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
News headline image
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade ↗
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
Via Investor's Business Daily
News headline image
Expert Ratings For Halozyme Therapeutics ↗
 
Via Benzinga
News headline image
Krystal Biotech Stock Sees RS Rating Jump To 91 ↗
On Tuesday, Krystal Biotech stock cleared a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88. 
Via Investor's Business Daily
News headline image
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio? ↗
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
Via Benzinga
News headline image
Halozyme Therapeutics Scores RS Rating Jump To 91 ↗
On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91. 
Via Investor's Business Daily
News headline image
This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
Halozyme Therapeutics +13% On Thursday: What's Going On? ↗
Halozyme Therapeutics surges as it raises FY24 guidance, driven by increased revenue projections and a new European patent for its drug delivery platform. 
Via Benzinga
Topics Intellectual Property
News headline image
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts ↗
 
Via Benzinga
News headline image
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying. ↗
In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating ↗
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating ↗
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
News headline image
The 3 Best Biotech Stocks to Buy in May 2024 ↗
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May. 
Via InvestorPlace
News headline image
When you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.